Major role for amphotericin B-flucytosine combination in severe cryptococcosis

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Dromer, Françoise ^a   Bernede Bauduin, Claire ^a,b   Guillemot, Didier ^a,b,c   Lortholary, Olivier ^a,d  

^a INSTITUT PASTEUR   (France)

^b INSERM U657   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FLUCYTOSINE; ANTIFUNGAL AGENT;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DEATH; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; FUNGUS CULTURE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MONOTHERAPY; NEUROIMAGING; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PRESCRIPTION; TERTIARY HEALTH CARE; TREATMENT DURATION; UNIVERSITY HOSPITAL; DRUG COMBINATION; DRUG EFFECT; ISOLATION AND PURIFICATION; MEDICAL SOCIETY; MULTICENTER STUDY; TREATMENT OUTCOME; UNITED STATES;

FILOBASIDIELLA NEOFORMANS;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG THERAPY, COMBINATION; FEMALE; FLUCYTOSINE; HIV SEROPOSITIVITY; HUMANS; MALE; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 51449121135     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002870     Document Type: Article

References (40)

1. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, et al. (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 326: 83-89.
2. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, et al. (1997) Treatment of cryptococcal meningitis associated with acquired immunodeficiency syndrome. N Engl J 337: 15-21.
3. Graybill JR, Sobel J, Saag M, van der Horst C, Powderly W, et al. (2000) Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 30: 47-54.
4. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Snade MA, et al. (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301: 126-131.
5. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, et al. (2000) Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 30: 710-718.
6. Dromer F, Mathoulin S, Dupont B, Brugière O, Letenneur L, et al. (1996) Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. Clin Infect Dis 22: 154-160.
7. Pappas PG (2001) Therapy of Cryptococcal Meningitis in non-HIV-infected Patients. Curr Infect Dis Rep 3: 365-370.
8. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, et al. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363: 1764-1767.
9. Robinson PA, Bauer M, Leal MAE, Evans SG, Holtom PD, et al. (1999) Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 28: 82-92.
10. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, and the French Cryptococcosis Study Group (2007) Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study. PLoS Med 4: e21:
11. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, et al. (2006) Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20: 2183-2191.
12. Hosmer D, Lemeshow S (2000) Applied Logistic Regression. Toronto: John Wiley & Sons.
13. Armitage P, Berry G, Matthews J (1994) Statistical methods in medical research. Oxford, England: Blackwell Science Ltd.
14. Micol R, Lortholary O, Sar B, Laureillard D, Ngeth C, et al. (2007) Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 45: 555-559.
15. McCarthy KIM, Morgan J, Wannemuehler KA, Mirza SA, Gould SM, et al. (2006) Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 20: 2199-2206.
16. Mirza SA, Phelan M, Rimland D, Graviss E, Hamill R, et al. (2003) The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 36: 789-794.
17. Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S (2007) Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res 5: 355-360.
18. White M, Cirrincione C, Blevins A, Armstrong D (1992) Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 165: 960-963.
19. Pitisuttithum P, Tansuphasawadikul S, Simpson AJH, Howe PA, White NJ (2001) A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 43: 226-233.
20. Perfect JR (2007) Management of cryptococcosis: how are we doing? PLoS Med 4: e47.
21. Lortholary O (2007) Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries. Clin Infect Dis 45: 81-83.
22. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, et al. (2005) Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19: 1043-1049.
23. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, et al. (2004) Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 189: 2185-2191.
24. Larsen RA, Pappas PG, Perfect J, Aberg JA, Casadevall A, et al. (2005) Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 49: 952-958.
25. Diamond RD, Bennett JE (1974) Prognostic factors in cryptococcal meningitis: a study 111 cases. Ann Intern Med 30: 176-181.
26. Brouwer AE, Teparrukkul P, Pinpraphaporn S, Larsen RA, Chierakul W, et al. (2005) Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J Infect Dis 192: 681-684.
27. Charlier C, Dromer F, Lévêque C, Chartier L, Cordoliani YS, et al. (2008) Brain Imaging Abnormalities' Correlation with Disease Severity during Cryptococcal Meningoencephalitis in HIV-positive Patients at HAART Era. PLoS One (in press).
28. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, et al. (1999) A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 28: 291-296.
29. Schwarz P, Dromer F, Lortholary O, Dannaoui E (2006) Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother 50: 113-120.
30. Schwarz P, Janbon G, Dromer F, Lortholary O, Dannaoui E (2007) Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 51: 383-385.
31. Dannaoui E, Abdul M, Arpin M, Michel-Nguyen A, Piens MA, et al. (2006) Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 50: 246-2470.
32. Larsen RA Bauer M, Brouwer AE, Sanchez A, Thomas AM, et al. (2007) In Vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis. Antimicrob Agents Chemother 51: 343-345.
33. Joly V, Aubry P, Ndayiragide A, Mlika-Cabanne N, Aboulker JP, et al. (1996) Randomized comparison of amphotericin B desoxycholate dissolved in dextrose or intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 23: 556-562.
34. Sharkey PK, Graybill JR, Johnoson ES, Hausrath SG, Pollard RB, et al. (1996) Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 22: 315-321.
35. Hamill R, Sobel J, El-Sadr W, Johnson P, Graybill J, et al. (1999) Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients (abstract 1161). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA.
36. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, et al. (2007) Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 45: 76-80.
37. Pappas P, Nolen T, Chetchotisakd P, Larsen R, Manosuthi W, et al. (2007) Fluconazole (Flu) Plus Amphotericin B (AmB) Versus AmB Alone for Primary Treatment of AIDS-Associated Cryptococcal Meningitis (CM): Results of a Phase II Trial. 46th Annual Conference on antimicrobial Agents and Chemotherapy San Francisco, CA.
38. Lortholary O, Nicolas M, Soreda S, Improvisi L, Ronin O, et al. (1999) Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. J Antimicrob Chemother 43: 817-824.
39. Larsen RA, Bauer M, Weiner JM, Diamond DM, Leal ME, et al. (1996) Effect of fluconazole on fungicidal activity of flucytosine in murinc: cryptococcal meningitis. Antimicrob Agems Chemother 40: 2178-2182.
40. Brouwer AE, van Kan HJ, Johnson E, Rajanuwong A, Teparrukkul P, et al. (2007) Oral versus intravenous flucytosine in patients with human inummodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother 51: 1038-1042.